This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zeuner, A. Articles by De Maria, R. Search for Related Content PubMed Articles by Zeuner, A. Articles by De Maria, R.

Chemotherapy-Induced Thrombocytopenia Derives from the Selective Death of Megakaryocyte Progenitors and Can Be Rescued by Stem Cell Factor

¹ Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy and ² Department of Experimental Oncology, Istituto Oncologico del Mediterraneo, Catania, Italy

Requests for reprints: Ann Zeuner, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. Phone: 39-6-4990-3121; Fax: 39-6-4938-7087; E-mail: a.zeuner{at}iss.it.

Thrombocytopenia is a common side effect of chemotherapy, responsible for increased risk of bleeding and delay of treatment schedules in cancer patients. It is currently unknown how chemotherapeutic agents affect platelet production and whether the platelet precursors megakaryocytes represent a direct target of cytotoxic drugs. We investigated the effects of chemotherapeutic agents on primary megakaryocytes by using a culture system that recapitulates in vitro human megakaryopoiesis and found that cytotoxic drugs predominantly destroyed megakaryocytic progenitors at early stages of differentiation. Immature megakaryocytes could be protected from chemotherapeutic agents by the cytokine stem cell factor (SCF), which binds the c-kit receptor expressed on hematopoietic stem and progenitor cells. In chemotherapy-treated megakaryocytes, SCF activated Akt, neutralized the mitochondrial apoptotic machinery, and inhibited caspase activity. Interfering with Akt activation abrogated the antiapoptotic effects of SCF, whereas exogenous expression of constitutively active Akt inhibited drug-induced apoptosis of primary megakaryocytes, indicating the Akt pathway as primarily responsible for SCF-mediated protection of megakaryocyte progenitors. These results indicate apoptosis of megakaryocyte progenitors as a major cause of chemotherapy-induced thrombocytopenia and suggest that SCF may be used to prevent platelet loss in cancer patients with c-kit–negative tumors. [Cancer Res 2007;67(10):4767–4773]

This article has been cited by other articles:

				M.A. Brieno-Enriquez, P. Robles, R. Garcia-Cruz, I. Roig, L. Cabero, F. Martinez, and M. Garcia Caldes A new culture technique that allows in vitro meiotic prophase development of fetal human oocytes Hum. Reprod., October 14, 2009; (2009) dep351v1. [Abstract] [Full Text] [PDF]

				J. J. O'Brien, S. L. Spinelli, J. Tober, N. Blumberg, C. W. Francis, M. B. Taubman, J. Palis, K. E. Seweryniak, J. M. Gertz, and R. P. Phipps 15-deoxy-{Delta}12,14-PGJ2 enhances platelet production from megakaryocytes Blood, November 15, 2008; 112(10): 4051 - 4060. [Abstract] [Full Text] [PDF]